When should nurses trigger the febrile neutropenia pathway?

Immediately upon meeting oral temperature thresholds with neutropaenia documented on the oncologic grid—obtain cultures when safe before antibiotics unless shock mandates parallel processes.

How fast should CBC trend after high-dose steroids?

Follow clinician-directed intervals; persistent unexplained leukocytosis or thrombocytopenia warrants haematology review rather than bedside interpretation silence.

Can rituximab be paused mid-infusion indefinitely without documentation?

No—timing, symptoms, meds given, restart criteria must populate the oncology reaction form for legal and safety governance.

Does negative interim PET negate infection vigilance?

Never—infection toxicity and second cancers remain active risks across cycles.

Who coordinates fertility preservation conversations?

Primary ownership sits with oncology MDT; nurses ensure referrals fire before gonadotoxic exposure when locally applicable.

Should travel vaccines proceed during maintenance?

Defer to haematology—live vaccines may be contra-indicated on active therapy.

What suffices for mucositis pain escalation?

Escalate when swallowing cessation, IV opioid requirement crosses protocol, or superinfection cues emerge.

How reconcile TB exposure history during staging?

Flag ID early—starting anti-TNF-like biologics or intensive steroids mandates context-sensitive testing pathways.

Can bone pain after G-CSF be ignored?

Document severity; escalating pain disproportionate to expected filgrastim myalgia warrants imaging review for marrow emergencies.

Lymphoma: Symptoms, Diagnosis, Treatment & Red Flags | NurseOnShift

🩸 Oncology · Haematological malignancy

Lymphoma: Symptoms, Diagnosis, Treatment & Red Flags

Hodgkin versus aggressive B-non-Hodgkin lymphoma pattern recognition, PET-CT-anchored Ann Arbor–Lugano staging, R-CHOP administration guardrails (rituximab teaching points in treatment section), marrow sampling context, and the febrile neutropenia first-hour workflow.

⏱️25 min read

📅Updated May 5, 2026

✓Medically Reviewed

✍️

Written by

Sid Ahmed Abdala Balal

RGN

🩺

Reviewed by

Nathalie Guerrero Camilo

✨

Featured snippet

Lymphoma is a family of lymphoid malignancies divided mainly into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL); treatment combines histology- and stage-directed chemoimmunotherapy (for many B-cell aggressive lymphomas, R-CHOP—rituximab plus CHOP—remains a familiar ward reference) with PET-informed response assessment. Febrile neutropenia after cytotoxics is a time-critical event: screen early, obtain cultures when safe, and activate the organisation’s empirical antibiotic bundle rather than expectant antipyretics alone.

Clinical snapshot: Think “nodes + systemic symptoms + PET stage + marrow when indicated,” then operationalise infusion reactions, cytopenia surveillance, and infection escalation thresholds every shift.

🔑Key Takeaways

Ann Arbor–Lugano with Deauville PET scoring underpins modern response reporting—nurses should read whether therapy is “PET-adapted” locally and what day-15/day-21 labs imply for the next cycle.
R-CHOP monitoring spans prednisone-linked hyperglycaemia and mood change, anthracycline cardiac surveillance triggers, ondansetron-responsive nausea/vomiting peaks, and rituximab infusion cytokine-release vigilance—the linked drug monographs sit in Treatment.
Fever + ANC below protocol cut-off after chemotherapy constitutes an oncologic emergency pathway—paired blood cultures (see escalation section) plus rapid clinician review beats “looks comfortable” reassurance.
Immunocompromise flags (HIV/AIDS, transplant, biologics) shift both lymphoma phenotype risk and infection differential—align isolation and referral with ID/haematology.
Teach patients B-symptom language—fever, drenching night sweats, unintended weight loss, disproportionate fatigue—early; pair with ECOG, hydration and oral-intake trending every clinic touchpoint.

⚡ Quick Facts

📊

US NHL rank (2026 est.)

~8th common new cancer

📍

HL median age (SEER)

~38 years at dx

⏱️

B symptoms triad

Fever, sweats, >10% wt loss

⚠️

Febrile neutropenia

Urgent eval + cultures

💡 Clinical Pearl

Inflammatory mimics: Tuberculosis and systemic autoimmune disease can produce persistent nodes and fever resembling lymphoma relapses—biopsy timing, traveller history, and HIV testing context matter before assuming progressive disease.

📋 Contents

❓

What is Lymphoma?

Lymphoma describes clonal proliferation of lymphocytes and their precursors that clinically behaves as a malignancy of the lymphoreticular system. Hodgkin lymphoma is defined by the presence of Hodgkin/Reed–Sternberg cells within an inflammatory background, most often presenting from nodal chains in young adults but spanning a wide age range; classical subtypes dominate practice discussions. Non-Hodgkin lymphoma is a heterogenous group originating from B-, T-, or NK-lineage cells, spanning indolent follicular processes through aggressive diffuse large B-cell phenotypes with divergent therapy and monitoring expectations.

Pathophysiology is not a single pathway: genetic lesions, viral co-factors (especially in immunosuppressed hosts), and microenvironmental immune evasion interact to produce nodal or extranodal masses, marrow infiltration, cytokine-driven systemic symptoms, and treatment vulnerabilities such as cytopenia and infection. Haematology/oncology nomenclature ties treatment to cell-of-origin and first-line trial data; nursing care bridges that taxonomy to observable infusion responses, laboratory trajectories, symptom control, and escalation when organ compromise or sepsis threatens the patient between specialist reviews.

📊

Staging & risk framing

Ann Arbor–Lugano remains the lingua franca on multidisciplinary reports: stages I–IV describe anatomical tumour extent, suffix E denotes extranodal contiguous spread, bulky disease thresholds appear on imaging narratives, and splenic involvement inherits stage logic from contemporary consensus updates. Functional imaging with PET, interpreted using Deauville scores, reshaped interim and end-of-treatment response language—know whether your centre documents PET-adapted plans because it changes expected cycle toxicity monitoring intensity.

Ann Arbor stage — ward-friendly translation cues
Stage	Clinical gist	Operational note
I–II	Limited nodal/regional burden	Radiotherapy adjuncts occasionally appear—skin care and fatigue teaching differ from systemic-only plans.
III	Both sides of diaphragm	Expect longer cytopenia windows; optimise nutrition and thromboprophylaxis per protocol.
IV	Disseminated extranodal or marrow/organ	Escalate new neurology, respiratory, or renal changes rapidly—disease and drug toxicity overlap.

On a small screen, swipe or scroll sideways to see the full table.

🚨Do not miss

Neutropenic fever after chemotherapy—activate emergency pathway, avoid sole reliance on antipyretics.
Airway-compromising neck mass, SVC syndrome features, or new stridor.
Spinal cord compression pain pattern with neuro deficit—steroids and urgent MRI discourse.
Tumour lysis metabolic triad context (K+, urate, phosphate) when bulky high-turnover therapy starts.

🔍

Clinical presentation

Painless lymphadenopathy is classic yet not universal; B symptoms (fever, drenching night sweats, unintended weight loss) flag systemic cytokine burden. Extramedullary cues—GI bleeding, obstructive jaundice, focal neuro signs—often indicate advanced or aggressive subtypes needing rapid imaging prioritisation rather than outpatient watchful waiting.

Atypical or population-specific cues

Older adults may emphasise cytopenias, infections, or fatigue rather than sizeable nodes.
Primary mediastinal large B-cell patterns can mimic infection or pulmonary embolism.
HIV-associated presentations may combine opportunistic illness—cross-check microbiology stewardship.

🦠

Causes & risk factors

Aetiology is multifactorial. Immunodeficiency states—including HIV/AIDS and pharmacologic immunosuppression—predispose to specific viral-driven lymphomas. Autoimmune inflammatory milieu—illustrated by long-standing Sjögren syndrome—associates with marginal-zone type thinking in risk conversations. Prior cytotoxic or radiotherapy exposure also shifts baseline surveillance expectations even when the index diagnosis is years old.

🔬

Diagnosis & investigations

Clinical assessment

Map node groups, document alcohol-related pain if volunteered, quantify B symptoms with calendar rigor, audit performance status, hydration, mucositis, and medication interactions before each cycle—not merely “stable on chart.”

Laboratory & pathology

Excisional or core biopsies with expert haematopathology underpin subtype assignment; marrow evaluation via bone marrow biopsy complements staging select cases. Serum LDH, albumin, and beta-2-microglobulin often contextualise tumour burden—not therapeutic targets themselves.

Imaging

PET-anchored metabolic imaging paired with staging CT backbone reporting forms the nodal extent and interim response narrative teams action each cycle.

🧠

Clinical decision flow

New unexplained lymphadenopathy + B symptoms → same-week specialist triage pathway.
Post-chemo temperature ≥ organisational threshold → sepsis screen + antibiotics per protocol ± G-CSF plan.
Infusion reactions → withhold rate increases, escalate per algorithm, preserve IV access lines.
Platelets <10–20×10⁹/L (local rules) without bleeding versus active haemorrhage → transfusion escalation branch.

🔄

Differential diagnoses

Mimic / alternative	Bedside discriminator
Leukemia	Peripheral blast crisis, marrow failure pattern—overlap requires flow cytometry narratives.
Multiple myeloma	Monoclonal protein storyline; lytic bone disease—distinct therapy yet shared supportive care motifs.
Tuberculosis	Adenopathy with endemic exposure; microscopy/NAAT before empirical steroids when feasible.
Reactive hyperplasia post-viral	Short evolution, tenderness, settling inflammatory markers—but biopsy if disproportionate duration.

On a small screen, swipe or scroll sideways to see the full table.

💊

Treatment options

Regimens are histology-tailored; below reflects themes nurses encounter beside aggressive B-cell protocols.

R-CHOP pattern: Rituximab day 1 infusion protocols, steroid pre-phase, anthracycline vesicant line management.
Supportive antiemetics: ondansetron schedules synced to highly emetogenic peaks.
Corticosteroids: hyperglycaemia checks on prednisone bursts—teach tapered plans only via prescriber.
Myeloid recovery: filgrastim timelines when febrile neutropenia prevention is scripted.
Stem-cell rescue / CAR-T cohorts: distinct cytokine-release monitoring—not interchangeable with outpatient R-CHOP teaching.

📋

Clinical practice considerations

Operationalise tumour board decisions into bedside tasks: hydration targets, urine output monitoring during high-risk electrolyte windows, antifungal/antiviral prophylaxis administration logs, contraception counselling around teratogenic agents, hepatitis B reactivation vigilance around anti-CD20 therapy, fertility referral documentation, mouth care bundles, neutrophil thresholds that postpone outpatient chemo desks, line patency stewardship, radiotherapy skin integrity checks—each item traced to timestamps and accountable clinicians rather than vague “onc aware” notes.

⚠️

Possible complications

Febrile neutropenia → sepsis.
Anaemia ± transfusion dependence → track Hb cues with blood product administration policies.
Cardiomyopathy (anthracycline cumulative).
Pneumonitis / bleomycin lung injury (HL regimens)—early oxygen needs deserve senior review.
Secondary myelodysplasia-years-out surveillance themes.

🛡️

Prevention & risk reduction

Clinician-facing prevention concentrates on vaccination planning per immunocompetence, suppressing preventable infections in HIV-linked lymphomas, antimicrobial stewardship aligning with microbiology advice, contraception fidelity around teratogens, hepatitis screening before biologics, and accurate sun-safe education when radiotherapy overlaps photosensitive drugs—not generic wellness copy.

📈

Prognosis & outlook

HL retains comparatively favourable stage-adjusted curves in contemporary series; diffuse large B-cell outcomes hinge on International Prognostic Index factors, marrow involvement, LDH burdens, and response-adapted strategies. Transparent discussions avoid both toxic positivity and nihilism—pair survival statistics from multidisciplinary meetings with symptom-control realism and documented advance-care preferences when appropriate.

👨‍⚕️

In clinical practice…

Hearing “just lymphoma follow-up” from patients—confirm exact cycle-day expectations and urgent hotline numbers written legibly.
Interpreter-led teaching for neutropenic diet and fever thresholds.
Wells/PE narratives may distract from mediastinal mass symptoms—maintain oncology voice in multidisciplinary huddles.
Document peripheral neuro exam before vinca alkaloids each cycle baseline.

📋

Bedside monitoring checklist

Temperature curves, infusion timers, hydration balance.
WCC/ANC/platelets per grid; flag delayed haematologic recovery trends.
Oral mucosa, bowel pattern, aspiration risk if neuro involvement.
ECG/LVEF scheduling reminders when flagged on oncology summary.

🚨

Emergency escalation

Activate urgent pathways for neutropenic sepsis, airway-threatening nodes, unexplained coma, presumed TLS with arrhythmia, massive haemorrhage, or seizures with posterior reversible encephalopathy syndrome suspicion in hypertensive steroid settings. Obtain cultures through sterile draws before antibiotics whenever minutes allow—the haematologist needs bug data.

🚨

Deterioration cues

Rising NEWS with subtle confusion often precedes septic shock—repeat lactate trends when protocolised. Falling SpO₂ separate from aspiration may herald PD-1 pneumonitis in checkpoint cohorts—a distinct escalation branch if applicable to your patient cohort.

🩺

Nursing management

Across diagnosis and therapy

Coordinate tumour lysis precaution bags, escalation teaching for caregivers, contraception fidelity, contraception bridging around admissions, hospice-sensitive symptom goals when salvage regimens cease benefit.

Chemotherapy administration

Vesicant line checks, hypersensitivity cart readiness, adherence to eyewash protocols, verifying cumulative dose trackers on charts.

Psychosocial & education

Teach recognising infection without delay; avoid implying “PET negative means stop worrying about fever.” Evaluate understanding using teach-back on temperature thresholds.

📚

NCLEX practice questions

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze on the topic of R-CHOP monitoring, Ann Arbor–Lugano PET staging literacy and febrile neutropenia triage, mirroring the Clinical Judgment Measurement Model emphasis on recognising instability and escalating within oncology pathways.

Unfolding case (Questions 1–3): Mr. Rao, 64, has diffuse large B-cell lymphoma completing R-CHOP Cycle 4. Tonight he spikes 38.5 °C oral, ANC 0.35×10⁹/L, BP 118/74, RR 20, denies rigors but describes mild lethargy. He received pegylated G-CSF analogue per protocol Cycle 3. Central line lumens flush stiffly overnight.

Question 1 · Type 1 — MCQ · Family A

Using your facility’s neutropenic fever bundle, what is the nurse’s FIRST priority action?

Encourage fluids and recheck temperature in four hours. Notify the oncology team urgently, initiate sepsis screen, obtain peripheral and line blood cultures prior to antimicrobials when safe, and prepare prescribed broad-spectrum antibiotics. Remove the central line independently and send catheter tip informal culture. Administer corticosteroid bolus to suppress fever cytokines without assessment.

Question 2 · SATA · Family C

Which histories support oncology suspicion requiring expedited biopsy work-up rather than simple reactive nodes? Select all that apply

Painless cervical nodes enlarging across six weeks with 6 kg unintended weight loss. Drenching night sweats disrupting sleep nightly for a month. Tender inguinal nodes after minor shaving abrasion resolving in five days. New PET report describing stage IV marrow involvement wording. Single asymptomatic pea-sized stable node eight years unchanged. Mediastinal mass image note with obstructive airway symptoms escalating.

Question 3 · SATA · Family E

08:00 labs: K⁺ 5.8 mmol/L, phosphate 2.4 mmol/L ↑, urate 520 µmol/L, creatinine ↑40% baseline; patient oliguric.

Which actions align with tumour lysis concern during induction therapy—flag for urgent haematology input? Select all that apply

Escalate for urgent medical review ± critical care escalation. Repeat ECG telemetry awareness for peaked T-waves hyperkalaemia. Encourage vigorous oral hydration only when potassium already high. Hold further nephrotoxins pending review checklist. Label trend “normal tumour load reduction” without senior review. Prepare high-acuity IV access optimisation per protocol.

Question 4 · MCQ · Family F

Four patients populate the oncology bay—who warrants FIRST bedside assessment?

Day −2 autologous stem-cell patient watching TV awaiting conditioning. Day +8 chemotherapy patient fever 39 °C, ANC 0.09, tachycardic new since last vitals hour. Stable clinic education slot reviewing wig options. Post-discharge refill call for stool softener constipation day 14.

Question 5 · Ordered · Family H

Rank initial ambulatory oncology triage tasks for unexplained painless nodes with B symptoms (1 = earliest).

Structured history + exam lymph regions
Blood baseline (CBC, LDH, renal/hepatic)
Imaging directed by haematology
Plan image-guided biopsy / node sampling
MDT oncology mapping post diagnosis

Question 6 · Matrix · Family G

Select most appropriate escalation tier.

Scenario	Routine	Same-day clinician	Emergency/RR
Cycle 5 day 1 pre-chem Labs stable teaching
ANC 0.29 fever spike new hour
Sudden inspiratory stridor bulky neck overnight
Controlled nausea relieved with PRN dose

On a small screen, swipe or scroll sideways to see the full matrix.

Question 7 · Cloze · Family I

Teaching after R-CHOP day 8 discharge: Fever ≥ unit threshold warrants . Always emphasise sterile mouth care and avoidance of overcrowded exposures during neutropenia .

Answer key & rationale

Next stepTimed NCLEX Next Gen–style scenarios on NurseOnShift